Last reviewed · How we verify
NCT06658925
Olverembatinib as Maintenance Therapy or Preemptive Therapy After Allo-HSCT in Ph+ALL
Phase 2 trial testing Olverembatinib is used to prevent recurrence or preemptive treatment after transplantation. in Ph+ Acute Lymphoblastic Leukemia (Ph+ALL) in 50 participants. Not yet recruiting.
31 August 2027
Quick facts
| Lead sponsor | Institute of Hematology & Blood Diseases Hospital, China |
|---|---|
| Phase | Phase 2 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 50 |
| Start date | 1 November 2024 |
| Primary completion | 31 August 2027 |
| Estimated completion | 31 August 2027 |
Drugs / interventions tested
- Olverembatinib is used to prevent recurrence or preemptive treatment after transplantation. — full drug profile →
Conditions studied
- Ph+ Acute Lymphoblastic Leukemia (Ph+ALL) — all drugs for Ph+ Acute Lymphoblastic Leukemia (Ph+ALL) →
- HSCT — all drugs for HSCT →
- Tyrosine Kinase Inhibitor — all drugs for Tyrosine Kinase Inhibitor →
Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Who can join
18 and older, any sex, with Ph+ Acute Lymphoblastic Leukemia (Ph+ALL) or HSCT. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is a single-center, prospective, single-arm exploratory study. Ph + acute lymphoblastic leukemia patients treated with allogeneic hematopoietic stem cell transplantation were recruited from the Stem Cell Transplantation Center of the Hospital of Hematology, Chinese Academy of Medical Sciences. The number of patients is expected to be 50 cases. The enrolled patients plan to receive Olverembatinib as a post-transplant treatment regimen, including maintenance therapy to prevent recurrence and preemptive treatment. Hematopoietic reconstitution ( neutrophil \> 0.5 × 10 \^ 9 / L, platelet \> 50 × 10 \^ 9 / L ) was evaluated after enrollment. From 2 months to 3 months after transplantation, Olverembatinib 40 mg QOD was added for maintenance treatment until 2 years after transplantation. During maintenance treatment, Olverembatinib dose ( dose range 20 mg QOD to 40 mg QOD ) can be adjusted according to blood picture, biochemical index or other oral drugs ( triazole drugs, etc. ).
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Current and emerging maintenance strategies after stem cell transplantation in children and adolescents with acute leukemias.
Rankin AW, Keating AK, Abu-Arja RF, Thakar MS, et al · · 2026 · PMID 41716469 · DOI 10.1016/j.omton.2026.201141 -
Olverembatinib (HQP1351): a third-generation tyrosine kinase inhibitor in the treatment of hematologic and solid malignancies-a comprehensive review of clinical outcomes.
Sadati S, Yazdizadeh S, Razavi SM, Homayoonfal M, et al · · 2026 · PMID 41547674 · DOI 10.1007/s12672-026-04438-x
Verify or expand the search:
- PubMed search for NCT06658925
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Institute of Hematology & Blood Diseases Hospital, China trials
Trials by the same sponsor.
- NCT06991920 — Immune-targeted Combination With Chemotherapy for Acute Leukemia of Ambiguous Lineage · NA · not yet recruiting
- NCT07407010 — BCMA/CD3 Bispecific Antibody as Bridging Therapy Before CAR-T Cell Infusion in RRMM · Phase 1 · not yet recruiting
- NCT07407140 — VAG Versus Standard Chemotherapy With FLT3 Inhibitor in Adult Patients With FLT3-Mutated AML · Phase 3 · not yet recruiting
- NCT07454226 — ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL · NA · not yet recruiting
- NCT07490288 — Venetoclax, Azacitidine and Liposomal Mitoxantrone for Newly Diagnosed AML · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06658925 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Institute of Hematology & Blood Diseases Hospital, China
- Last refreshed: 26 October 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06658925.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing